Skip to Content

View Additional Section Content

GY005 - A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or –Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

For more information on this trial, click the link below.

Clinical Trial Categories

  • Ovarian Cancer
Contact
Ashley Douglas, RN at 215-481-4429

Location

  • Asplundh Cancer Pavilion
    3941 Commerce Ave.
    Willow Grove, PA 19090

Find a Physician
Search Our Directory

215-481-MEDI
215-481-6334

Schedule a
Test

215-481-EXAM
215-481-3926